Physician profile
Anit Garg
NPI 1750358990
$1,761.30
in general payments reported to CMS, 2019-2025
27 companies · $842 in 2025
The $842 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.65 · 2020: $61.48 · 2021: $143 · 2022: $239 · 2023: $89.37 · 2024: $367 · 2025: $842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,299.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,298.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $265.07 | 2021-2022 | |
| Depuy Synthes Sales INC. | $173.03 | 2022-2024 | Embotrap |
| Pfizer INC. | $153.21 | 2024-2025 | |
| Abbvie INC. | $149.67 | 2024-2025 | |
| Lilly USA, LLC | $134.98 | 2024-2025 | Zepbound, Mounjaro, Kisunla |
| Novo Nordisk INC | $108.18 | 2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $86.29 | 2024-2025 | Airsupra, Farxiga |
| Boston Scientific Corporation | $81.34 | 2025 | Watchman Access System, General - Pain Management |
| Amgen INC. | $78.23 | 2021-2025 | Repatha, Evenity, Prolia |
| Glaxosmithkline, LLC. | $73.61 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Medtronic Vascular, INC. | $61.48 | 2020 | |
| Dynavax Technologies Corporation | $47.19 | 2024-2025 | Heplisav-B |
| Exact Sciences Corporation | $39.95 | 2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $37.42 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Phathom Pharmaceuticals, INC. | $35.25 | 2024 | Voquezna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $28.37 | 2025 | Rexulti |
| W. L. Gore & Associates, INC. | $27.15 | 2021 | |
| Sanofi Pasteur INC. | $22.69 | 2025 | |
| Phadia US INC. | $19.46 | 2025 | Immunocap |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.34 | 2025 | Xifaxan |
| Medtronic, INC. | $19.20 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.11 | 2024 | Xarelto |
| Cranial Technologies, INC | $18.38 | 2025 | Doc Band |
| Abbott Laboratories | $17.44 | 2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $15.57 | 2024 | |
| Antares Pharma, INC. | $15.27 | 2025 | Xyosted |
| Dexcom, INC. | $14.42 | 2025 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anit Garg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.